2/5
09:15 am
mbrx
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Medium
Report
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
1/13
09:02 am
mbrx
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects [Yahoo! Finance]
Medium
Report
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects [Yahoo! Finance]
1/13
08:55 am
mbrx
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
Medium
Report
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
1/12
08:55 am
mbrx
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs [Yahoo! Finance]
Low
Report
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs [Yahoo! Finance]
1/12
08:36 am
mbrx
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Low
Report
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
12/17
08:31 am
mbrx
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
High
Report
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
12/15
02:08 pm
mbrx
Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at Roth Capital.
Medium
Report
Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at Roth Capital.
12/11
07:20 am
mbrx
Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/10
08:30 am
mbrx
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
High
Report
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
12/9
08:07 am
mbrx
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
High
Report
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
12/8
08:21 am
mbrx
Moleculin Announces New Annamycin Collaboration in Brain Tumors
Medium
Report
Moleculin Announces New Annamycin Collaboration in Brain Tumors
11/26
10:30 am
mbrx
Moleculin Announces Reverse Stock Split [Yahoo! Finance]
Medium
Report
Moleculin Announces Reverse Stock Split [Yahoo! Finance]
11/26
09:15 am
mbrx
Moleculin to Participate in the Virtual Investor Closing Bell Series
Low
Report
Moleculin to Participate in the Virtual Investor Closing Bell Series
11/26
09:08 am
mbrx
Moleculin to execute 1-for-25 reverse stock split [Seeking Alpha]
Medium
Report
Moleculin to execute 1-for-25 reverse stock split [Seeking Alpha]
11/26
09:00 am
mbrx
Moleculin Announces Reverse Stock Split
High
Report
Moleculin Announces Reverse Stock Split
11/13
08:51 am
mbrx
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented [Yahoo! Finance]
Low
Report
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented [Yahoo! Finance]
11/13
08:36 am
mbrx
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
Medium
Report
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
11/12
09:01 am
mbrx
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill [Yahoo! Finance]
Low
Report
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill [Yahoo! Finance]
11/12
08:37 am
mbrx
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
Low
Report
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill